Skip to main content

Bensen Daniel's Form 4 filing

Tyra Biosciences, Inc. (TYRA) · filed Jun 28, 2023

Accession no.
0001209191-23-040105
Filed
Jun 28, 2023
Trade date
Jun 26-28, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 8 non-derivative transactions and 3 derivative transactions. Open-market sales total $788.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bensen DanielCIK 0001880946Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 26, 2023Common StockMOption exerciseAcquired+17,232$0.61+$10,511.52545,213Direct
Jun 26, 2023Common StockSSaleDisposed−10,862$16.49F2−$179,114.38534,351Direct
Jun 26, 2023Common StockSSaleDisposed−6,370$17.24F3−$109,818.8527,981Direct
Jun 27, 2023Common StockMOption exerciseAcquired+16,028$0.61+$9,777.08544,009Direct
Jun 27, 2023Common StockSSaleDisposed−7,893$16.73F4−$132,049.89536,116Direct
Jun 27, 2023Common StockSSaleDisposed−8,135$17.09F5−$139,027.15527,981Direct
Jun 28, 2023Common StockMOption exerciseAcquired+13,524$0.61+$8,249.64541,505Direct
Jun 28, 2023Common StockSSaleDisposed−13,524$16.91F6−$228,690.84527,981Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 26, 2023Common StockMOption exerciseDisposed−17,232$0.00$0211,830Direct
Jun 27, 2023Common StockMOption exerciseDisposed−16,028$0.00$0195,802Direct
Jun 28, 2023Common StockMOption exerciseDisposed−13,524$0.00$0182,278Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.01 to $17.005. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.02 to $17.69. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.01 to $17.01. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F5

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.02 to $17.20. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F6

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.50 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)